Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Patients with alcoholic liver disease (ALD) or non-alcoholic liver disease (NAFLD) were found to exhibit low hepatic GSH levels, which were replenished after oral AdoMet treatment (1.2 g/day for 6 months) [77]
Secondary end points included body-weight reductions of more than or equal to 20%, 25%, and 30%
(6) explicit RUO designation with no language implying human use
Improves skin health from the inside out
doi: 10.2147/ijn.s273713 Summary Keywords immunosuppression, immunotherapy resistance, nanomedicine delivery systems, osteosarcoma, translational oncology, tumor microenvironment (TME) Citation Huang Q, Yu G, Shi B and Deng T (2026) Engineering immunity in osteosarcoma: nanomedicine strategies for overcoming immune evasion
